We focused on immune cell markers (CD3, CD4, CD8, CD20) as lymphocytes are relatively regular in size and shape and we did not include CD16 and K17 in this evaluation since the myeloid and tumor cells are irregular in size and shape. This evidence concerns the gene CD8A and neoplasm.